---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-054910"
form_type: "8-K"
ticker: "IMNM"
cik: "0001472012"
company_name: "Immunome Inc."
filed_at: "2024-04-30T23:59:59+00:00"
generated_at: "2026-06-03T04:17:32.959871+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Immunome VP Finance/PAO Bob Lapetina resigns; Max Rosett named PAO effective May 10

## Summary
- Bob Lapetina resigned as VP Finance, Corporate Controller and principal accounting officer effective May 10, 2024; departure not due to disagreement.
- Max Rosett appointed principal accounting officer effective May 10, 2024; he currently serves as Interim CFO, EVP Operations since December 2023.
- Rosett previously held roles at Morphimmune and Research Bridge Partners; no new material plan or contract entered in connection with appointment.

## SEC filing metadata
- accession: 0001104659-24-054910
- form_type: 8-K
- ticker: IMNM
- cik: 0001472012
- company_name: Immunome Inc.
- filed_at: 2024-04-30T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472012/000110465924054910/0001104659-24-054910-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472012/000110465924054910/tm2413152d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-054910
- JSON: https://secwatch.observer/filing/0001104659-24-054910.json
- Plain text: https://secwatch.observer/filing/0001104659-24-054910.txt

## Key facts
- Executive change
  Max Rosett was appointed as principal accounting officer at Immunome Inc..
  - Action: appointed
  - Role: principal accounting officer
  source text: the Company’s board of directors appointed Max Rosett, in addition to his other titles, as the Company’s principal accounting officer effective immediately upon the effectiveness of Mr. Lapetina’s resignation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472012/000110465924054910/0001104659-24-054910-index.htm
- Executive change
  Bob Lapetina departed as Vice President, Finance, Corporate Controller, and principal accounting officer at Immunome Inc..
  - Action: resigning
  - Role: Vice President, Finance, Corporate Controller, and principal accounting officer
  source text: Bob Lapetina notified Immunome, Inc. (the “Company”) that he will be resigning from his positions as the Company’s Vice President, Finance, Corporate Controller, and principal accounting officer to pursue other opportunities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472012/000110465924054910/0001104659-24-054910-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.